{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:50:23Z","timestamp":1793155823434,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":136,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.jtauto.2021.100104","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T12:48:22Z","timestamp":1621946902000},"page":"100104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Distinct roles of interleukin-17 and T helper 17\u00a0cells among autoimmune diseases"],"prefix":"10.1016","volume":"4","author":[{"given":"Shintaro","family":"Akiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2519-6129","authenticated-orcid":false,"given":"Atsushi","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtauto.2021.100104_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.71.1.1","article-title":"IL-17: prototype member of an emerging cytokine family","volume":"71","author":"Aggarwal","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jtauto.2021.100104_bib2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jtauto.2021.100104_bib3","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.4049\/jimmunol.155.12.5483","article-title":"Human IL-17: a novel cytokine derived from T cells","volume":"155","author":"Yao","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2021.100104_bib4","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1084\/jem.183.6.2593","article-title":"T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines","volume":"183","author":"Fossiez","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jtauto.2021.100104_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1189\/jlb.0211099","article-title":"Mechanisms controlling Th17 cytokine expression and host defense","volume":"90","author":"McAleer","year":"2011","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jtauto.2021.100104_bib6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.immuni.2008.03.004","article-title":"The biological functions of T helper 17 cell effector cytokines in inflammation","volume":"28","author":"Ouyang","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.jtauto.2021.100104_bib7","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jtauto.2021.100104_bib8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jtauto.2021.100104_bib9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature04754","article-title":"Transforming growth factor-beta induces development of the T(H)17 lineage","volume":"441","author":"Mangan","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jtauto.2021.100104_bib10","doi-asserted-by":"crossref","first-page":"9358","DOI":"10.1074\/jbc.C600321200","article-title":"STAT3 regulates cytokine-mediated generation of inflammatory helper T cells","volume":"282","author":"Yang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jtauto.2021.100104_bib11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/MOG.0000000000000402","article-title":"Mouse models of inflammatory bowel disease for investigating mucosal immunity in the intestine","volume":"33","author":"Bamias","year":"2017","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"2","key":"10.1016\/j.jtauto.2021.100104_bib12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jaci.2020.04.034","article-title":"Animal models of psoriasis-highlights and drawbacks","volume":"147","author":"Schon","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jtauto.2021.100104_bib13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00281-017-0622-4","article-title":"Arthritis models: usefulness and interpretation","volume":"39","author":"Bessis","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.jtauto.2021.100104_bib14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2021.100104_bib15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2021.100104_bib16","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2021.100104_bib17","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2021.100104_bib18","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17a in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2021.100104_bib19","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jtauto.2021.100104_bib20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2021.100104_bib21","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtauto.2021.100104_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2021.100104_bib23","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2021.100104_bib24","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jtauto.2021.100104_bib25","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jtauto.2021.100104_bib26","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe crohn's disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jtauto.2021.100104_bib27","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2021.100104_bib28","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/gut.2007.135053","article-title":"IL23 differentially regulates the Th1\/Th17 balance in ulcerative colitis and Crohn's disease","volume":"57","author":"Kobayashi","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.jtauto.2021.100104_bib29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bpg.2018.05.016","article-title":"Can IL-23 be a good target for ulcerative colitis?","volume":"32\u201333","author":"Allocca","year":"2018","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.jtauto.2021.100104_bib30","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/0016-5085(90)90290-H","article-title":"A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice","volume":"98","author":"Okayasu","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtauto.2021.100104_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clim.2003.09.013","article-title":"Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice","volume":"110","author":"Ogawa","year":"2004","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jtauto.2021.100104_bib32","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ni.1736","article-title":"A protective function for interleukin 17A in T cell-mediated intestinal inflammation","volume":"10","author":"O'Connor","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jtauto.2021.100104_bib33","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ni0609-568","article-title":"IL-17A directly inhibits TH1 cells and thereby suppresses development of intestinal inflammation","volume":"10","author":"Awasthi","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jtauto.2021.100104_bib34","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1097\/MIB.0b013e318286fa1c","article-title":"TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis, Inflamm","volume":"19","author":"Wedebye Schmidt","year":"2013","journal-title":"Bowel Dis"},{"key":"10.1016\/j.jtauto.2021.100104_bib35","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1172\/JCI118861","article-title":"Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses","volume":"98","author":"Berg","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jtauto.2021.100104_bib36","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI21404","article-title":"IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6","volume":"116","author":"Yen","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jtauto.2021.100104_bib37","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1053\/j.gastro.2007.03.104","article-title":"Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice","volume":"132","author":"Elson","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtauto.2021.100104_bib38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1462-5822.2011.01577.x","article-title":"Intestinal microbiota, evolution of the immune system and the bad reputation of pro-inflammatory immunity","volume":"13","author":"Ohnmacht","year":"2011","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.jtauto.2021.100104_bib39","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3389\/fimmu.2017.00397","article-title":"Immune responses to broad-spectrum antibiotic treatment and fecal microbiota transplantation in mice","volume":"8","author":"Ekmekciu","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2021.100104_bib40","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.chom.2008.09.009","article-title":"Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine","volume":"4","author":"Ivanov","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jtauto.2021.100104_bib41","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1126\/science.1198469","article-title":"Induction of colonic regulatory T cells by indigenous Clostridium species","volume":"331","author":"Atarashi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jtauto.2021.100104_bib42","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cell.2009.09.033","article-title":"Induction of intestinal Th17 cells by segmented filamentous bacteria","volume":"139","author":"Ivanov","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jtauto.2021.100104_bib43","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1128\/IAI.01513-13","article-title":"Induction of bacterial antigen-specific colitis by a simplified human microbiota consortium in gnotobiotic interleukin-10-\/- mice","volume":"82","author":"Eun","year":"2014","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jtauto.2021.100104_bib44","doi-asserted-by":"crossref","first-page":"21536","DOI":"10.1073\/pnas.1922189117","article-title":"Defined microbiota transplant restores Th17\/RORgammat(+) regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas","volume":"117","author":"Britton","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jtauto.2021.100104_bib45","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.immuni.2018.12.015","article-title":"Microbiotas from humans with inflammatory bowel disease alter the balance of gut Th17 and RORgammat(+) regulatory T cells and exacerbate colitis in mice","volume":"50","author":"Britton","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jtauto.2021.100104_bib46","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtauto.2021.100104_bib47","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.4049\/jimmunol.160.7.3513","article-title":"IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages","volume":"160","author":"Jovanovic","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2021.100104_bib48","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4049\/jimmunol.161.1.409","article-title":"Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines","volume":"161","author":"Chabaud","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2021.100104_bib49","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/1529-0131(200109)44:9<2176::AID-ART371>3.0.CO;2-4","article-title":"Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a \"fine-tuning cytokine\" in inflammation processes","volume":"44","author":"Katz","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2021.100104_bib50","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/1529-0131(200109)44:9<2078::AID-ART358>3.0.CO;2-J","article-title":"Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci","volume":"44","author":"LeGrand","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2021.100104_bib51","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/ard.61.8.704","article-title":"Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines","volume":"61","author":"Koshy","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2021.100104_bib52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.30093","article-title":"Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production","volume":"63","author":"van Hamburg","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2021.100104_bib53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/ar1478","article-title":"The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models","volume":"7","author":"Lubberts","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jtauto.2021.100104_bib54","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","article-title":"IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis","volume":"103","author":"Kotake","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jtauto.2021.100104_bib55","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1359\/jbmr.1999.14.9.1513","article-title":"Interleukin-17: a new bone acting cytokine in vitro","volume":"14","author":"Van bezooijen","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jtauto.2021.100104_bib56","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","article-title":"Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study","volume":"72","author":"Genovese","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2021.100104_bib57","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40070","article-title":"Secukinumab in active rheumatoid arthritis: a phase III randomized, double-blind, active comparator- and placebo-controlled study","volume":"69","author":"Blanco","year":"2017","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2021.100104_bib58","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.38617","article-title":"A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors","volume":"66","author":"Genovese","year":"2014","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2021.100104_bib59","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/ar4347","article-title":"A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis","volume":"15","author":"Martin","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jtauto.2021.100104_bib60","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"Boehncke","year":"2015","journal-title":"Psoriasis, Lancet"},{"key":"10.1016\/j.jtauto.2021.100104_bib61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jtauto.2021.100104_bib62","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jtauto.2021.100104_bib63","doi-asserted-by":"crossref","first-page":"7423","DOI":"10.4049\/jimmunol.180.11.7423","article-title":"Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes","volume":"180","author":"Pene","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2021.100104_bib64","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4049\/jimmunol.1100123","article-title":"Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis","volume":"187","author":"Lin","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2021.100104_bib65","first-page":"957","volume":"376","author":"Ritchlin","year":"2017","journal-title":"Psoriatic Arthritis, N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2021.100104_bib66","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtauto.2021.100104_bib67","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/ng.3528","article-title":"Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci","volume":"48","author":"Ellinghaus","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jtauto.2021.100104_bib68","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/ard.2006.064543","article-title":"The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice","volume":"66","author":"Vander Cruyssen","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2021.100104_bib69","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/annrheumdis-2014-206323","article-title":"Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis","volume":"74","author":"Ciccia","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2021.100104_bib70","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells,","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.jtauto.2021.100104_bib71","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/apt.15397","article-title":"Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents","volume":"50","author":"Yamada","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jtauto.2021.100104_bib72","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.14309\/crj.2018.56","article-title":"Rapid onset of inflammatory bowel disease after receiving secukinumab infusion","volume":"5","author":"Wang","year":"2018","journal-title":"ACG Case Rep. J."},{"key":"10.1016\/j.jtauto.2021.100104_bib73","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2016.09.026","article-title":"Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data","volume":"76","author":"Strober","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jtauto.2021.100104_bib74","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2021.100104_bib75","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jaad.2020.04.010","article-title":"Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors","volume":"83","author":"Wright","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jtauto.2021.100104_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233781","article-title":"Risk for development of inflammatory bowel disease under inhibition of interleukin 17: a systematic review and meta-analysis","volume":"15","author":"Burisch","year":"2020","journal-title":"PloS One"}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909021000241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909021000241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:36:32Z","timestamp":1762904192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909021000241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":76,"alternative-id":["S2589909021000241"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2021.100104","relation":{},"ISSN":["2589-9090"],"issn-type":[{"value":"2589-9090","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct roles of interleukin-17 and T helper 17\u00a0cells among autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2021.100104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100104"}}